Halberd Corporation2020-09-14T13:05:54-04:00

Moving Forward

Halberd Corporation (HALB) patented extracorporeal treatment is applicable to many hard-to-cure blood-borne and neurologic diseases, including Covid-19, other viruses, PTSD, cancer, etc.

COVID-19

Halberd Corporation (HALB) patented extracorporeal treatment is applicable to many hard-to-cure blood-borne and neurologic diseases, including Covid-19, other viruses, PTSD, cancer, etc.

PTSD

Halberd Corporation (HALB) patented extracorporeal treatment is applicable to many hard-to-cure blood-borne and neurologic diseases, including Covid-19, other viruses, PTSD, cancer, etc.

Chronic Traumatic Encephalopathy

Halberd Corporation (HALB) patented extracorporeal treatment is applicable to many hard-to-cure blood-borne and neurologic diseases, including Covid-19, other viruses, PTSD, cancer, etc.

Cancer

Halberd Corporation (HALB) patented extracorporeal treatment is applicable to many hard-to-cure blood-borne and neurologic diseases, including Covid-19, other viruses, PTSD, cancer, etc.

Halberd Corporation has acquired exclusive licenses to two issued patents and four provisional patent applications related to the extracorporeal treatment of blood-borne diseases and Cerebrospinal Fluid related diseases, with particular focus on the treatment and rapid detection of Covid-19 and other virus’. The issued patents’ extracorporeal technology is applicable to a significant number of the most debilitating and often fatal illnesses affecting mankind: PTSD, CTE (Chronic Traumatic Encephalopathy) and Cancer, among others.

We have developed an aggressive timetable to advance the development of these breakthrough technologies through laboratory, hospital, and clinical trials. In addition, we have initiated the development of potential patient trial application lists. Our management team has extensive experience and contacts in the medical/pharmaceutical fields as well as a demonstrated track record of launching new business ventures in a competitive environment.

Halberd Corporation Fact Sheet

A brief review of some of Halberd’s significant accomplishments and recent developments.

PROPRIETARY SEQUENTIAL DIALYSIS TECHNIQUE

A methodology that physically removes the pathophysiologic basis of the disease

The Company’s proprietary Sequential Dialysis Technique is a methodology that physically removes the pathophysiologic basis of the disease, eliminating it without dangerous side effects.

  • Superior to current treatments which eliminate the presence of most illnesses but often with catastrophic or even fatal side effects.
  • Subtractive therapy (removal of harmful molecules) reduces risks associated with conventional “Additive” therapy (adding chemicals to the body).
  • Targets Covid-19 and similar viral diseases initially, with future efforts to develop treatments for Alzheimer’s Disease, PTSD/Traumatic Brain Injury, and cancer.
View all patents

Halberd News

Press releases and updates on our medical breakthroughs.

Halberd Corporation Files International Patent Cooperation Treaty (PCT) Application on Covid-19 Inflammatory Cytokine Storm Treatment

Jackson Center, PA, April 12, 2021 – Halberd Corporation (OTC-PINK: "HALB") filed an International Patent Cooperation Treaty (PCT) application for coverage of the invention titled, “Covid-19 Inflammatory Cytokine Storm Treatment.”  The Patent Cooperation Treaty has over 150 participating countries and allows an inventor to seek patent protection in numerous countries simultaneously. William ...

Halberd Corporation CEO Letter

Q1-21 Accomplishments and Q2 Plans Jackson Center, PA, April 6, 2021 Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC-PINK: HALB) It has been a very busy and fruitful first quarter of 2021.  Often, people get so wrapped up in the day-to-day events that we lose sight of just how far ...

Halberd Corporation’s Scientific Breakthrough: Conjugating Metallic Particles to SARS-CoV-2 and E. Coli Antigens

Paves Way for Disease Elimination by Radio Frequency Waves Jackson Center, PA, March 30, 2021 – Halberd Corporation (OTC-PINK: "HALB") has successfully conjugated (joined) metallic nanoparticles with its patent-pending SARS-CoV-2 antibody, while still maintaining the antibody’s antigen-neutralizing properties.  This was a key scientific hurdle to overcome in implementing its patent-pending extracorporeal disease ...

View all news
Go to Top